{
  "guid": "07d3964c-8600-451f-b87d-37cc691a3d81",
  "title": "'Some Hope Is Better Than Having No Hope'",
  "description": "<p>When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.</p><p>But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.</p><p>What is the story behind this new drug?</p><p>Guest: <a href=\"https://www.nytimes.com/by/pam-belluck?smid=pc-thedaily\">Pam Belluck</a>, a health and science writer for The New York Times.  </p><p><a href=\"https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily\">Sign up here</a> to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, <a href=\"https://www.nytimes.com/newsletters/the-daily?module=inline\">subscribe to our newsletter</a>. </p><p>Background reading: </p><ul><li><a href=\"https://www.nytimes.com/2021/06/08/business/aducanumab-alzheimers-cost.html\">Aduhelm, also known as aducanumab</a>, was approved despite<a href=\"https://www.nytimes.com/2021/06/07/health/aduhelm-fda-alzheimers-drug.html\"> opposition from the F.D.A.’s independent advisory committee</a> and some Alzheimer’s experts.</li><li>Even those who supported the F.D.A.’s approval have said that authorizing it for anyone with the disease<a href=\"https://www.nytimes.com/2021/06/21/health/aduhelm-alzheimers-drug.html\"> is much too broad</a>.</li></ul><p>For more information on today’s episode, visit <a href=\"http://nytimes.com/thedaily?smid=pc-thedaily\">nytimes.com/thedaily</a>. Transcripts of each episode will be made available by the next workday. </p>\n",
  "pubDate": "Wed, 7 Jul 2021 09:45:00 +0000",
  "author": "thedaily@nytimes.com (The New York Times)",
  "link": "https://www.nytimes.com/the-daily",
  "content:encoded": "<p>When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.</p><p>But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.</p><p>What is the story behind this new drug?</p><p>Guest: <a href=\"https://www.nytimes.com/by/pam-belluck?smid=pc-thedaily\">Pam Belluck</a>, a health and science writer for The New York Times.  </p><p><a href=\"https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily\">Sign up here</a> to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, <a href=\"https://www.nytimes.com/newsletters/the-daily?module=inline\">subscribe to our newsletter</a>. </p><p>Background reading: </p><ul><li><a href=\"https://www.nytimes.com/2021/06/08/business/aducanumab-alzheimers-cost.html\">Aduhelm, also known as aducanumab</a>, was approved despite<a href=\"https://www.nytimes.com/2021/06/07/health/aduhelm-fda-alzheimers-drug.html\"> opposition from the F.D.A.’s independent advisory committee</a> and some Alzheimer’s experts.</li><li>Even those who supported the F.D.A.’s approval have said that authorizing it for anyone with the disease<a href=\"https://www.nytimes.com/2021/06/21/health/aduhelm-alzheimers-drug.html\"> is much too broad</a>.</li></ul><p>For more information on today’s episode, visit <a href=\"http://nytimes.com/thedaily?smid=pc-thedaily\">nytimes.com/thedaily</a>. Transcripts of each episode will be made available by the next workday. </p>\n",
  "enclosure": "",
  "itunes:title": "'Some Hope Is Better Than Having No Hope'",
  "itunes:author": "The New York Times",
  "itunes:duration": "00:36:59",
  "itunes:summary": "When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.\nBut the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.\nWhat is the story behind this new drug?\n\nGuest: Pam Belluck, a health and science writer for The New York Times.",
  "itunes:subtitle": "When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.\nBut the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.\nWhat is the story behind this new drug?\n\nGuest: Pam Belluck, a health and science writer for The New York Times.",
  "itunes:explicit": "no",
  "itunes:episodeType": "full"
}